PON1-108 TT and PON1-192 RR genotypes are more frequently encountered in Greek PCOS than non-PCOS women, and are associated with hyperandrogenemia

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: MON 548-560-Hyperandrogenic Disorders
Basic/Clinical
Monday, June 17, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board MON-550
George Paltoglou*1, George Tavernarakis1, Panagiotis Christopoulos2, Margarita Vlassi1, Maria Gazouli1, Efthimios Deligeoroglou1, George Creatsas1 and Georgios Mastorakos1
1Athens Medical School, Athens, Greece, 2Athens Medical School
Objective: To investigate the frequencies of three paraoxonase (PON)1 polymorphisms in Greek polycystic ovary syndrome (PCOS) and non-PCOS women, and their genotypes association with hyperandrogenemia and insulin resistance.

Design: Case–control genetic association study.

Setting: University Hospital Endocrine Unit.

Patients: 142 PCOS cases (NIH criteria) and 112 controls.

Main Outcome Measure: Genotyping of the c.–108C>T (PON1-108), the c.163T>A (PON1-55) and the c.575A>G (PON1-192) polymorphisms and measurement of baseline androgen and insulin resistance profile.

Results: The PON1-108 TT and PON1-192 RR genotypes were more frequently encountered in the PCOS than in the control group. The PON1-192 R allele frequency was greater in the PCOS than in the control group. Comparing the PCOS and the control groups, statistical significances favored a recessive and a dominant genetic model, respectively, for the single PON1-108 T and PON1-192 R alleles. Free Androgen Index (FAI) levels were higher in patients with PON1-108 TT, while Testosterone, FAI and Dehydroepiandrosterone sulfate (DHEAS) levels were higher in patients with PON1-192 RR than patients with the wild or the heterozygous genotype.

Conclusions: The decreased PON1 activity-associated PON1-108 TT and the PON1-192 RR genotypes are more frequently found in Greek PCOS women and are associated with hyperandrogenemia. Hyperandrogenemia must depend also on other genetic factors because the same genotypes were not associated with hyperandrogenemia in the control group. Through identification of the involved polymorphisms women with PCOS could potentially have a better therapeutic screening.

Nothing to Disclose: GP, GT, PC, MV, MG, ED, GC, GM

*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm